The effect of omega-3 fatty acids on the atherogenic lipoprotein phenotype in patients with nephrotic range proteinuria

Clinical Nephrology

Volumn 77, Issue 6, 2012, Pages 445-453

  Bell, Samira ^a   Cooney, Josephine ^b   Packard, Christopher J ^b   Caslake, Muriel J ^b   Deighan, Christopher J ^c  

^a NINEWELLS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Lipids; Lipoproteins; Nephrotic; Omega 3 fatty acids

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID;

ADULT; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; NEPHROTIC SYNDROME; PHENOTYPE; TRIACYLGLYCEROL BLOOD LEVEL; AGED; ATHEROSCLEROSIS; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG COMBINATION; MIDDLE AGED; NEPHROSIS; PROTEINURIA; TIME; TREATMENT OUTCOME; UNITED KINGDOM;

AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DRUG COMBINATIONS; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS; MALE; MIDDLE AGED; NEPHROSIS; PHENOTYPE; PROTEINURIA; SCOTLAND; TIME FACTORS; TREATMENT OUTCOME;

EID: 84864564273     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107450     Document Type: Article

References (29)

1. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. The atherogenic lipoprotein phenotype: small dense LDL and lipoprotein remnants in nephrotic range proteinuria. Atherosclerosis. 2001; 157: 211-220.
2. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, Shepherd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis. 1994; 106: 241-253.
3. Tomono S, Kawazu S, Kato N, Ono T, Ishii C, Ito Y, Shimizu M, Shimoyama M, Nakano T, Nakajima K. Uptake of remnant like particles (RLP) in diabetic patients from mouse peritoneal macrophages. J Atheroscler Thromb. 1994; 1: 98-102.
4. Masuoka H, Kamei S, Wagayama H, Ozaki M, Kawasaki A, Tanaka T, Kitamura M, Katoh S, Shintani U, Misaki M, Sugawa M, Ito M, Nakano T. Association of remnant-like particle cholesterol with coronary artery disease in patients with normal total cholesterol levels. Am Heart J. 2000; 139: 305-310.
5. Hooper L, Thompson RL, Harrison RA, Summerbell CD, Moore H, Worthington HV, Durrington PN, Ness AR, Capps NE, Davey Smith G, Riemersma RA, Ebrahim SB. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev. 2004; CD003177.
6. Hopper L, Ness A, Higgins JP, Moore T, Ebrahim S. GISSI-Prevenzione trial. Lancet. 1999; 354: 1557.
7. von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999; 130: 554-562. PubMed.
8. Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B, Jordan HS, Lau J. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr. 2006; 84: 5-17. PubMed.
9. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997; 65 (Suppl): 1645-1654. PubMed.
10. Nestel PJ, Connor WE, Reardon MF, Connor S, Wong S, Boston R. Suppression by diets rich in fish oil of very low density lipoprotein production in man. J Clin Invest. 1984; 74: 82-89.
11. Sanders TA, Sullivan DR, Reeve J, Thompson GR. Triglyceride-lowering effect of marine polyunsaturates in patients with hypertriglyceridemia. Arteriosclerosis. 1985; 5: 459-465.
12. Harris WS, Connor WE, Alam N, Illingworth DR. Reduction of postprandial triglyceridemia in humans by dietary n-3 fatty acids. J Lipid Res. 1988; 29: 1451-1460.
13. Nozaki S, Garg A, Vega GL, Grundy SM. Postheparin lipolytic activity and plasma lipoprotein response to omega-3 polyunsaturated fatty acids in patients with primary hypertriglyceridemia. Am J Clin Nutr. 1991; 53: 638-642.
14. Weintraub MS, Grosskopf I, Rassin T, Miller H, Charach G, Rotmensch HH, Liron M, Rubinstein A, Iaina A. Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years. BMJ. 1996; 312: 935-939.
15. Lindsey S, Pronczuk A, Hayes KC. Low density lipoprotein from humans supplemented with n-3 fatty acids depresses both LDL receptor activity and LDLr mRNA abundance in HepG2 cells. J Lipid Res. 1992; 33: 647-658.
16. Roach PD, Kambouris AM, Trimble RP, Topping DL, Nestel PJ. The effects of dietary fish oil on hepatic high density and low density lipoprotein receptor activities in the rat. FEBS Lett. 1987; 222: 159-162.
17. Abbey M, Clifton P, Kestin M, Belling B, Nestel P. Effect of fish oil on lipoproteins, lecithin: cholesterol acyltransferase, and lipid transfer protein activity in humans. Arteriosclerosis. 1990; 10: 85-94.
18. Calabresi L, Donati D, Pazzucconi F, Sirtori CR, Franceschini G. Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. Atherosclerosis. 2000; 148: 387-396.
19. Lipid Research Clinical Manual of Laboratory Operations. D.H.E.W Publications, 1975: 75-628.
20. Caslake MJ, Packard CJ. The use of ultracentrifugation for the separation of lipoproteins. In: Rifai, Warnick, Dominiczak, editors. Handbook of Lipoprotein Testing. AACC Press, 2000: 625-646.
21. Griffin BA, Caslake MJ, Yip B, Tait GW, Packard CJ, Shepherd J. Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis. 1990; 83: 59-67.
22. Levey AS, Greene T, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11: A0828.
23. Rivellese AA, Maffettone A, Vessby B, Uusitupa M, Hermansen K, Berglund L, Louheranta A, Meyer BJ, Riccardi G. Effects of dietary saturated, monounsaturated and n-3 fatty acids on fasting lipoproteins, LDL size and post-prandial lipid metabolism in healthy subjects. Atherosclerosis. 2003; 167: 149-158.
24. Law MR, Wald NJ. An ecological study of serum cholesterol and ischaemic heart disease between 1950 and 1990. Eur J Clin Nutr. 1994; 48: 305-325.
25. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994; 308: 367-372.
26. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003; 326: 1423.
27. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ Coordinating Committee of the National Cholesterol Education Program. A summary of implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol. 2004; 24: 1329-1330.
28. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360: 7-22.
29. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease. J Am Soc Nephrol. 2001; 12: 341-348.